Literature DB >> 12200993

Abscess tonsillectomy for acute peritonsillar abscess.

S Knipping1, M Passmann, Th Schrom, A Berghaus.   

Abstract

Peritonsillar abscess (PTA) is a common but potentially serious complication of acute exudative tonsillitis. Several treatment guidelines have been described including needle aspiration, incision and drainage or abscess tonsillectomy. From January 1996 to September 2000 145 patients (53 female and 92 male, age range 3-95 years) were treated for PTA at the Department of Otorhinolaryngology, Head and Neck Surgery of the MLU Halle-Wittenberg, Germany. The highest incidence of PTA was observed in the second and third decades of life. Immediate abscess tonsillectomy was performed in 105 cases. This procedure, considered as safe and easy, has a lot of advantages. Compared with other treatments, it removes the abscess with amelioration of the trismus and dysphagia. Needle aspiration as the initial and only treatment was performed in 13 patients. In 20 patients without clinical improvement after aspiration, abscess tonsillectomy was undertaken. We conclude that immediately performed abscess tonsillectomy is an effective and safe treatment for peritonsillar abscess.

Entities:  

Mesh:

Year:  2002        PMID: 12200993

Source DB:  PubMed          Journal:  Rev Laryngol Otol Rhinol (Bord)        ISSN: 0035-1334


  4 in total

Review 1.  [Therapy options for peritonsillar abscess].

Authors:  P Federspil
Journal:  HNO       Date:  2009-03       Impact factor: 1.284

2.  [Bilateral peritonsillar abscess with lymph node abscess in a infant. A rare case].

Authors:  F Bast; H Köhler; K-D Sparr; T Schrom
Journal:  HNO       Date:  2011-10       Impact factor: 1.284

3.  [Trends and complications in the management of peritonsillar abscess with emphasis on children].

Authors:  J P Windfuhr; S Remmert
Journal:  HNO       Date:  2005-01       Impact factor: 1.284

Review 4.  [Is postoperative antibiotic treatment mandatory after abscess tonsillectomy].

Authors:  S Knipping; S Löwe; C Lautenschläger; T Schrom
Journal:  HNO       Date:  2009-03       Impact factor: 1.284

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.